Razan Mohty, MD
@razanmohty.bsky.social
Assistant Professor @uabmedicine @ONealCancerUAB | Leukemia, BMT& Cellular therapy | @moffittnews ’23| @MayoClinic ’22 | @AUB_Lebanon ’21 | My posts are my own
Happy to share our recent manuscript on outcomes of anti-CD19 #CART for #lymphoma in octogenarians (80 years of age or older).
👉🏻CR rate 71.4%
👉🏻1-year OS 61.2%
👉🏻1-year PFS 47.6%
👉🏻1-year NRM 11.6%
🙏🏻 to all collaborators
Link 🔗 rdcu.be/ebQ47
👉🏻CR rate 71.4%
👉🏻1-year OS 61.2%
👉🏻1-year PFS 47.6%
👉🏻1-year NRM 11.6%
🙏🏻 to all collaborators
Link 🔗 rdcu.be/ebQ47
Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study
Bone Marrow Transplantation - Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study
rdcu.be
March 2, 2025 at 2:28 AM
Happy to share our recent manuscript on outcomes of anti-CD19 #CART for #lymphoma in octogenarians (80 years of age or older).
👉🏻CR rate 71.4%
👉🏻1-year OS 61.2%
👉🏻1-year PFS 47.6%
👉🏻1-year NRM 11.6%
🙏🏻 to all collaborators
Link 🔗 rdcu.be/ebQ47
👉🏻CR rate 71.4%
👉🏻1-year OS 61.2%
👉🏻1-year PFS 47.6%
👉🏻1-year NRM 11.6%
🙏🏻 to all collaborators
Link 🔗 rdcu.be/ebQ47
Reposted by Razan Mohty, MD
Our new @BMTCTN 1703 analysis busts a few myths:
- QOL improved with ptCY
- 🩸Cystitis not worse
- 2yr GRFS superior 42% vs 29%, p=0.001
- ptCY relapse NOT higher
@sghmd.bsky.social TY to Mike Martens for elegant analysis #GvHD #alloHCT #BMT
ascopubs.org/doi/10.1200/...
- QOL improved with ptCY
- 🩸Cystitis not worse
- 2yr GRFS superior 42% vs 29%, p=0.001
- ptCY relapse NOT higher
@sghmd.bsky.social TY to Mike Martens for elegant analysis #GvHD #alloHCT #BMT
ascopubs.org/doi/10.1200/...
Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703
The BMT CTN 1703 phase III trial confirmed that graft-versus-host disease (GVHD) prophylaxis
with post-transplantation cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate
mofetil (MMF) result...
ascopubs.org
January 5, 2025 at 4:55 PM
Our new @BMTCTN 1703 analysis busts a few myths:
- QOL improved with ptCY
- 🩸Cystitis not worse
- 2yr GRFS superior 42% vs 29%, p=0.001
- ptCY relapse NOT higher
@sghmd.bsky.social TY to Mike Martens for elegant analysis #GvHD #alloHCT #BMT
ascopubs.org/doi/10.1200/...
- QOL improved with ptCY
- 🩸Cystitis not worse
- 2yr GRFS superior 42% vs 29%, p=0.001
- ptCY relapse NOT higher
@sghmd.bsky.social TY to Mike Martens for elegant analysis #GvHD #alloHCT #BMT
ascopubs.org/doi/10.1200/...
Reposted by Razan Mohty, MD
Two incredibly important abstracts presented by @moffittnews.bsky.social myeloma investigators at #ASH24. 1/3
December 10, 2024 at 7:13 PM
Two incredibly important abstracts presented by @moffittnews.bsky.social myeloma investigators at #ASH24. 1/3
Reposted by Razan Mohty, MD
Dr. Jabbour from @mdanderson.bsky.social presents on long-term outcomes following obecabtagene autoleucel (obe-cel, Aucatzyl) stratified by depth of response by clonoSEQ NGS (sensitivity 10^-6). 84% of responders achieved clonoSEQ negativity. 1/x #ash24 #allsm
December 10, 2024 at 1:09 AM
Dr. Jabbour from @mdanderson.bsky.social presents on long-term outcomes following obecabtagene autoleucel (obe-cel, Aucatzyl) stratified by depth of response by clonoSEQ NGS (sensitivity 10^-6). 84% of responders achieved clonoSEQ negativity. 1/x #ash24 #allsm
Reposted by Razan Mohty, MD
On my way to @ash-hematology.bsky.social #ASH24 & sharing this starterpack for HCT, #CARTcells & #genetherapy - > 100 members DM/comment if I missed someone #bmtsm #mmsm #leusm #lymsm #sicklecell #mpnsm #medsky
go.bsky.app/7xxh8WW
go.bsky.app/7xxh8WW
December 5, 2024 at 12:32 PM
On my way to @ash-hematology.bsky.social #ASH24 & sharing this starterpack for HCT, #CARTcells & #genetherapy - > 100 members DM/comment if I missed someone #bmtsm #mmsm #leusm #lymsm #sicklecell #mpnsm #medsky
go.bsky.app/7xxh8WW
go.bsky.app/7xxh8WW
How I Treat #BPDCN
@ash-hematology.bsky.social @mkd-bmt.bsky.social #ASH24 #leusm
ashpublications.org/blood/articl...
@ash-hematology.bsky.social @mkd-bmt.bsky.social #ASH24 #leusm
ashpublications.org/blood/articl...
December 5, 2024 at 4:16 AM
Reposted by Razan Mohty, MD
December 3, 2024 at 12:17 PM
Reposted by Razan Mohty, MD
If you're interested in Stem cell transplant and/or Cellular Therapy this is the list #bmtsm #CARTcells #leusm #mmsm #lymsm #MedSky #TcellRx go.bsky.app/7xxh8WW
November 22, 2024 at 2:33 PM
If you're interested in Stem cell transplant and/or Cellular Therapy this is the list #bmtsm #CARTcells #leusm #mmsm #lymsm #MedSky #TcellRx go.bsky.app/7xxh8WW
Reposted by Razan Mohty, MD
Hello, #hematology community! ASH is now on BlueSky.
We're here to share cutting-edge research and educational resources and connect global experts in blood diseases.
Join us in advancing hematology together. Welcome, colleagues!
#BloodSky #HemeSky #MedSky
We're here to share cutting-edge research and educational resources and connect global experts in blood diseases.
Join us in advancing hematology together. Welcome, colleagues!
#BloodSky #HemeSky #MedSky
November 21, 2024 at 5:15 PM
Hello, #hematology community! ASH is now on BlueSky.
We're here to share cutting-edge research and educational resources and connect global experts in blood diseases.
Join us in advancing hematology together. Welcome, colleagues!
#BloodSky #HemeSky #MedSky
We're here to share cutting-edge research and educational resources and connect global experts in blood diseases.
Join us in advancing hematology together. Welcome, colleagues!
#BloodSky #HemeSky #MedSky